Macquarie Group LTD Supernus Pharmaceuticals, Inc. Transaction History
Macquarie Group LTD
- $90.3 Billion
- Q3 2024
A detailed history of Macquarie Group LTD transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Macquarie Group LTD holds 2,631,897 shares of SUPN stock, worth $103 Million. This represents 0.09% of its overall portfolio holdings.
Number of Shares
2,631,897
Previous 2,679,796
1.79%
Holding current value
$103 Million
Previous $71.7 Million
14.48%
% of portfolio
0.09%
Previous 0.08%
Shares
29 transactions
Others Institutions Holding SUPN
# of Institutions
285Shares Held
60.5MCall Options Held
27.7KPut Options Held
11.3K-
Black Rock Inc. New York, NY10.4MShares$407 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.13MShares$240 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY5.1MShares$200 Million2.64% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.88MShares$113 Million0.02% of portfolio
-
State Street Corp Boston, MA2.16MShares$84.4 Million0.0% of portfolio
About SUPERNUS PHARMACEUTICALS, INC.
- Ticker SUPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,495,300
- Market Cap $2.09B
- Description
- Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...